Health Technology Assessments

Reimbursement “Furies” Real, But Won’t Avenge Pharma Til 2017, Says Citi

Posted on Dec 4, 2012 in Adherence, Company, Cost/Comparative Effectiveness, Diagnostics, Health Technology Assessments, Medical Innovation, Payer Management Tool, Payers: Commercial, Payers: Managed Medicaid/Medicare, Payment Reform, Pharmaceuticals, Pricing

“Beware the Three Furies,” warns Citi analyst Andrew Baum.  In a report for pharma investors published Nov. 29., Baum turns to classical mythology to describe shared savings models, drug pathways...

Learn More

Sanofi Blinks First: Zaltrap Price Cut Proves HTA Has Reached The US

Posted on Nov 12, 2012 in Company, Cost/Comparative Effectiveness, Health Technology Assessments, Medical Innovation, Payer Management Tool, Payers: Commercial, Payers: Managed Medicaid/Medicare, Payment Reform, Pharmaceuticals, Pricing, Product Launch, Value-based pricing

Sanofi’s decision last week to cut the price of its colon cancer drug Zaltrap by up to 50% showed that the US market is no longer immune to European-style drug price pressure. Never mind that the move...

Learn More